Merck Completes Acquisition of Acceleron Pharma Inc.
22 November 2021 - 10:45PM
Business Wire
Merck (NYSE: MRK), known as MSD outside the United States and
Canada, today announced the successful completion of the
acquisition of Acceleron Pharma Inc. (Nasdaq: XLRN).
“This is an important and strategic opportunity for our company
to continue growing our cardiovascular portfolio and pipeline, that
builds on our long and proud legacy in cardiovascular disease and
further bolsters our business development strategy,” said Rob
Davis, chief executive officer and president, Merck. “Fueled by
Acceleron’s groundbreaking research, we are excited to explore the
opportunities and possibilities ahead to reach even more patients
by addressing this critical health need.”
Acceleron is focused on harnessing the power of the transforming
growth factor (TGF)-beta superfamily of proteins that is known to
play a central role in the regulation of cell growth,
differentiation and repair. Acceleron’s lead therapeutic candidate,
sotatercept, has a novel mechanism of action with the potential to
improve short-term and/or long-term clinical outcomes in patients
with pulmonary arterial hypertension (PAH), a progressive and
life-threatening blood vessel disorder. Sotatercept is in Phase 3
trials as add-on to current standard of care for the treatment of
PAH.
About Merck
For over 130 years, Merck, known as MSD outside of the United
States and Canada, has been inventing for life, bringing forward
medicines and vaccines for many of the world’s most challenging
diseases in pursuit of our mission to save and improve lives. We
demonstrate our commitment to patients and population health by
increasing access to health care through far-reaching policies,
programs and partnerships. Today, Merck continues to be at the
forefront of research to prevent and treat diseases that threaten
people and animals – including cancer, infectious diseases such as
HIV and Ebola, and emerging animal diseases – as we aspire to be
the premier research-intensive biopharmaceutical company in the
world. For more information, visit www.merck.com and connect with
us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
There can be no guarantees with respect to pipeline candidates that
the candidates will receive the necessary regulatory approvals or
that they will prove to be commercially successful. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of the global outbreak of novel coronavirus disease
(COVID-19); the impact of pharmaceutical industry regulation and
health care legislation in the United States and internationally;
global trends toward health care cost containment; technological
advances, new products and patents attained by competitors;
challenges inherent in new product development, including obtaining
regulatory approval; the company’s ability to accurately predict
future market conditions; manufacturing difficulties or delays;
financial instability of international economies and sovereign
risk; dependence on the effectiveness of the company’s patents and
other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise, except to the extent required by law.
Additional factors that could cause results to differ materially
from those described in the forward-looking statements can be found
in the company’s 2020 Annual Report on Form 10-K and the company’s
other filings with the Securities and Exchange Commission (SEC)
available at the SEC’s Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211122005755/en/
Media Contacts:
Jessica Fine (908) 608-4859
Melissa Moody (215) 407-3536
Investor Contacts:
Peter Dannenbaum (908) 740-1037
Steven Graziano (908) 740-6582
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024